A share price of Century Therapeutics Inc [IPSC] is currently trading at $0.55, down -1.02%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IPSC shares have gain 5.64% over the last week, with a monthly amount glided 1.95%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Century Therapeutics Inc [NASDAQ: IPSC] stock has seen the most recent analyst activity on August 08, 2024, when Rodman & Renshaw initiated its Buy rating and assigned the stock a price target of $6. Previously, JP Morgan downgraded its rating to Neutral on August 28, 2023, and dropped its price target to $5. On December 27, 2022, Chardan Capital Markets initiated with a Buy rating and assigned a price target of $19 on the stock. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $15 on October 31, 2022. Canaccord Genuity initiated its recommendation with a Buy and recommended $28 as its price target on October 10, 2022. H.C. Wainwright started tracking with a Buy rating for this stock on May 23, 2022, and assigned it a price target of $27. In a note dated May 12, 2022, William Blair initiated an Mkt Perform rating.
Century Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.34 and $3.47. Currently, Wall Street analysts expect the stock to reach $15 within the next 12 months. Century Therapeutics Inc [NASDAQ: IPSC] shares were valued at $0.55 at the most recent close of the market. An investor can expect a potential return of 2627.27% based on the average IPSC price forecast.
Analyzing the IPSC fundamentals
Trailing Twelve Months sales for Century Therapeutics Inc [NASDAQ:IPSC] were 114.90M which represents 12667.72% growth. Gross Profit Margin for this corporation currently stands at -0.04% with Operating Profit Margin at -0.29%, Pretax Profit Margin comes in at -0.18%, and Net Profit Margin reading is -0.19%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is -0.11 and Total Capital is -0.11. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Century Therapeutics Inc [NASDAQ:IPSC] is 11.70. Further, the Quick Ratio stands at 11.70, while the Cash Ratio is 3.58. Considering the valuation of this stock, the price to sales ratio is 0.42, the price to book ratio is 0.20.
Transactions by insiders
Recent insider trading involved Pfeiffenberger Brent, Officer, that happened on May 16 ’25 when 29552.0 shares were purchased. Chief Operations Officer, Farid Adrienne completed a deal on May 05 ’25 to sell 1024.0 shares. Meanwhile, SVP Finance & Operations Carr Douglas sold 295.0 shares on May 05 ’25.
